Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Status:
Completed
Trial end date:
2019-09-09
Target enrollment:
Participant gender:
Summary
As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of
immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The
combination treatment is being evaluated in a non-randomized, multi-cohort study as
post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or
peritoneal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoVaccine Technologies, Inc. ImmunoVaccine Technologies, Inc. (IMV Inc.)